Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18421977 | 0.89 | LPAR3 (0.40) | LPAR3LPAR2LPAR1TSHRGABBR2 | |
| SCHEMBL10138078 | 0.87 | GABBR2 (0.41) | LPAR3LPAR2LPAR1TSHRGABBR2 | |
| SCHEMBL14365001 | 0.82 | — | — | |
| SCHEMBL11315928 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 | |
| SCHEMBL21569439 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 | |
| SCHEMBL21569457 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 | |
| SCHEMBL21569461 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 | |
| SCHEMBL20738949 | 0.81 | CYP3A4 (0.43) | LPAR3LPAR2LPAR1TSHRLMNA | |
| SCHEMBL10827406 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 | |
| SCHEMBL10826446 | 0.81 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030683-A2 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7989429-B2 | LNA antagonists targeting the androgen receptor | ENZON PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, LHCGR | LPAR3 16/4885LPAR2 31/4885LPAR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.